Oxford Nanopore Technologies PLC Reports First‑Half Revenue Miss

Oxford Nanopore Technologies PLC, listed on the London Stock Exchange, announced on 13 July 2026 that its first‑half revenue fell short of expectations. The company cited a decline in Chinese sales as a key factor behind the shortfall, while noting that the outlook for the remainder of the year remains unchanged.

Financial Impact

  • Stock reaction: Shares fell sharply, hitting a 52‑week low of 104 GBX on 8 April 2026 before sliding to 120.3 GBX at close on 9 July 2026. The latest trading session saw a further decline, with the share price dropping to the lowest level seen since early April.
  • Market sentiment: Analyst coverage is mixed. Bergens Bank Research reduced its price target to 220 GBX (from 230 GBX), while Deutsche Bank Research maintained a “BUY” rating. Goldman Sachs and HSBC also issued “BUY” recommendations, keeping target prices largely unchanged.

Business Highlights

  • Sector focus: The company operates in the health‑care sector, specializing in molecular detection and analysis technologies. Its products are used in DNA sequencing, diagnostics, drug development, biomolecular interaction, ion‑channel screening, and defense applications.
  • Geographic exposure: Revenue from China represents a significant portion of the company’s top line; the current weakness in that market has materially affected performance.

Outlook

Oxford Nanopore has not altered its guidance for the rest of the year, indicating confidence that the underlying business model remains robust despite the temporary dip in revenue. The company continues to emphasize its role as a leader in molecular detection and analysis, with a global customer base and ongoing product development pipeline.

The market will be watching for further updates on China’s economic environment and the company’s ability to rebound from the current shortfall.